GT201600017A - Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen - Google Patents
Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienenInfo
- Publication number
- GT201600017A GT201600017A GT201600017A GT201600017A GT201600017A GT 201600017 A GT201600017 A GT 201600017A GT 201600017 A GT201600017 A GT 201600017A GT 201600017 A GT201600017 A GT 201600017A GT 201600017 A GT201600017 A GT 201600017A
- Authority
- GT
- Guatemala
- Prior art keywords
- indolizine
- pharmaceutical compositions
- compositions containing
- preparation procedure
- new derivatives
- Prior art date
Links
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical class C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS DERIVADOS DE INDOLIZINA, A SU PROCEDIMIENTO DE PREPARACIÓN Y A LAS COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN. LOS COMPUESTOS DE LA PRESENTE INVENCIÓN SON NUEVOS Y PRESENTAN CARACTERÍSTICAS FARMACOLÓGICAS MUY INTERESANTES EN EL CAMPO DE LA APOPTOSIS Y DE LA CANCEROLOGÍA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1357265A FR3008976A1 (fr) | 2013-07-23 | 2013-07-23 | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201600017A true GT201600017A (es) | 2018-10-08 |
Family
ID=50023640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201600017A GT201600017A (es) | 2013-07-23 | 2016-01-22 | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |
Country Status (49)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2986002B1 (fr) | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008976A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
| TWI759316B (zh) | 2016-07-22 | 2022-04-01 | 法商施維雅藥廠 | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 |
| WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| PT3697785T (pt) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Compostos de imidazopiridina como inibidores de pad |
| FR3072679B1 (fr) | 2017-10-25 | 2020-10-30 | Servier Lab | Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| PT3704120T (pt) | 2017-11-24 | 2024-07-03 | Jubilant Episcribe Llc | Compostos heterocíclicos como inibidores de prmt5 |
| BR112020018610A2 (pt) | 2018-03-13 | 2020-12-29 | Jubilant Prodel LLC | Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas |
| CA3138307A1 (en) * | 2019-05-13 | 2020-11-19 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
| JP2024508948A (ja) * | 2021-03-12 | 2024-02-28 | エイル セラピューティクス，インコーポレイテッド | Ｂｃｌ－２阻害剤としてのテトラヒドロインドリジン－１－カルボキサミドを有する化合物 |
| TW202408588A (zh) | 2022-05-20 | 2024-03-01 | 瑞士商諾華公司 | 抗體-藥物結合物抗腫瘤化合物及其使用方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100391958C (zh) * | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US20050070570A1 (en) | 2003-06-18 | 2005-03-31 | 4Sc Ag | Novel potassium channels modulators |
| ZA200702257B (en) * | 2004-08-20 | 2009-06-24 | Univ Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
| WO2006023778A2 (en) * | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| CN101356159A (zh) | 2005-12-22 | 2009-01-28 | 惠氏公司 | 经取代异喹啉-1,3(2h,4h)-二酮类、1-硫代-1,4-二氢-2h-异喹啉-3-酮类和1,4-二氢-3(2h)-异喹啉酮类以及其作为激酶抑制剂的用途 |
| US7902218B2 (en) | 2006-12-12 | 2011-03-08 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinolines as β-secretase inhibitors |
| AU2008242983B2 (en) | 2007-04-16 | 2013-07-11 | Abbvie Inc. | 7-substituted indole Mcl-1 inhibitors |
| PT2149560E (pt) | 2007-05-22 | 2015-07-13 | Astellas Pharma Inc | Composto de tetra-hidroisoquinolina substituído na posição 1 |
| CN102007101A (zh) | 2007-11-30 | 2011-04-06 | 生物区科学管理控股有限公司 | 作为抗菌剂的四氢-异喹啉ppat抑制剂 |
| AU2009215191A1 (en) | 2008-02-13 | 2009-08-20 | Gilead Connecticut, Inc. | 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
| PL2252317T3 (pl) | 2008-02-15 | 2014-09-30 | Univ Tufts | Leczenie zwyrodnienia plamki żółtej |
| WO2012162365A1 (en) * | 2011-05-25 | 2012-11-29 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
| US20140357633A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| KR20140107573A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
| BR112014015308A8 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos para inibição da interação de bcl2 com contrapartes de ligação |
| MX2014007725A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| BR112014015322A8 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos e composições para inibir a interação de bcl2 com parceiros de ligação |
| DK2609926T3 (da) | 2011-12-30 | 2014-01-06 | Jakob Hraschan | Forebyggelse eller behandling af smertefulde polyneuropatier ved administration af et aluminiumsilikat |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008979B1 (fr) | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008976A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
-
2013
- 2013-07-23 FR FR1357265A patent/FR3008976A1/fr active Pending
-
2014
- 2014-06-16 JO JOP/2014/0193A patent/JO3310B1/ar active
- 2014-06-24 UY UY35626A patent/UY35626A/es unknown
- 2014-07-03 TW TW103123060A patent/TWI511969B/zh not_active IP Right Cessation
- 2014-07-21 AR ARP140102678A patent/AR099913A1/es unknown
- 2014-07-22 CU CU2016000011A patent/CU24380B1/es unknown
- 2014-07-22 PT PT147586051T patent/PT3024833T/pt unknown
- 2014-07-22 TN TN2016000014A patent/TN2016000014A1/fr unknown
- 2014-07-22 DK DK14758605.1T patent/DK3024833T3/en active
- 2014-07-22 MX MX2016000906A patent/MX365916B/es active IP Right Grant
- 2014-07-22 RS RS20171036A patent/RS56451B1/sr unknown
- 2014-07-22 EP EP14758605.1A patent/EP3024833B1/fr active Active
- 2014-07-22 CA CA2918217A patent/CA2918217C/fr active Active
- 2014-07-22 UA UAA201601430A patent/UA119243C2/uk unknown
- 2014-07-22 AU AU2014294867A patent/AU2014294867B2/en active Active
- 2014-07-22 RU RU2016105999A patent/RU2693629C2/ru active
- 2014-07-22 MD MDA20160016A patent/MD4643C1/ro not_active IP Right Cessation
- 2014-07-22 ES ES14758605.1T patent/ES2650814T3/es active Active
- 2014-07-22 MY MYPI2016700108A patent/MY178251A/en unknown
- 2014-07-22 JP JP2016528588A patent/JP6458029B2/ja active Active
- 2014-07-22 BR BR112016001328-0A patent/BR112016001328B1/pt active IP Right Grant
- 2014-07-22 US US14/906,330 patent/US9944620B2/en active Active
- 2014-07-22 LT LTEP14758605.1T patent/LT3024833T/lt unknown
- 2014-07-22 SG SG10201800580XA patent/SG10201800580XA/en unknown
- 2014-07-22 HU HUE14758605A patent/HUE037498T4/hu unknown
- 2014-07-22 NZ NZ716156A patent/NZ716156A/en unknown
- 2014-07-22 PE PE2016000036A patent/PE20160240A1/es active IP Right Grant
- 2014-07-22 WO PCT/FR2014/051885 patent/WO2015011397A1/fr active Application Filing
- 2014-07-22 SI SI201430461T patent/SI3024833T1/sl unknown
- 2014-07-22 ME MEP-2017-272A patent/ME02922B/me unknown
- 2014-07-22 KR KR1020167004588A patent/KR102007516B1/ko active IP Right Grant
- 2014-07-22 SG SG11201600318RA patent/SG11201600318RA/en unknown
- 2014-07-22 CN CN201480052171.7A patent/CN105579450B/zh active Active
- 2014-07-22 PL PL14758605T patent/PL3024833T3/pl unknown
- 2014-07-22 EA EA201600124A patent/EA030323B1/ru unknown
- 2014-07-22 NO NO14758605A patent/NO3024833T3/no unknown
- 2014-07-22 AP AP2016008990A patent/AP2016008990A0/xx unknown
- 2014-07-22 MA MA38803A patent/MA38803A1/fr unknown
-
2016
- 2016-01-08 PH PH12016500057A patent/PH12016500057A1/en unknown
- 2016-01-12 CL CL2016000063A patent/CL2016000063A1/es unknown
- 2016-01-13 DO DO2016000014A patent/DOP2016000014A/es unknown
- 2016-01-15 ZA ZA2016/00350A patent/ZA201600350B/en unknown
- 2016-01-15 CR CR20160031A patent/CR20160031A/es unknown
- 2016-01-21 SA SA516370448A patent/SA516370448B1/ar unknown
- 2016-01-21 NI NI201600015A patent/NI201600015A/es unknown
- 2016-01-21 IL IL243742A patent/IL243742B/en active IP Right Grant
- 2016-01-22 GT GT201600017A patent/GT201600017A/es unknown
- 2016-09-06 HK HK16110596.9A patent/HK1222394A1/zh unknown
- 2016-10-04 HK HK16111561.8A patent/HK1223360A1/zh not_active IP Right Cessation
-
2017
- 2017-11-14 HR HRP20171752TT patent/HRP20171752T1/hr unknown
- 2017-12-05 CY CY20171101271T patent/CY1119652T1/el unknown
-
2018
- 2018-02-27 US US15/906,389 patent/US10414754B2/en active Active
-
2019
- 2019-08-06 US US16/532,834 patent/US20190359595A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201600017A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| GT201400142A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| NI201400079A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ECSP14008757A (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| CR20160076A (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA | |
| CO7210068A1 (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| UY35467A (es) | Compuestos orgánicos | |
| UY35469A (es) | Moduladores de p2x7 | |
| CR20150447A (es) | Nuevos derivados de pirazol | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| CR20150204A (es) | Nuevos derivados de piridina | |
| CR20150511A (es) | Nuevos derivados de purina | |
| CL2018001493A1 (es) | Nuevos derivados de fenilo | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY35653A (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
| DOP2016000064A (es) | Derivados de fenilalanina sustituidos | |
| UY35922A (es) | Derivados de sulfonamidas tricíclicas | |
| CR20150641U (es) | Composiciones farmacéuticas | |
| GT201200066A (es) | Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CO7010833A2 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY35443A (es) | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina |